Radiotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Radiotherapy, including details on cancer treatment, side effects.

Combined use of sodium borocaptate and buthionine sulfoximine in boron neutron capture therapy enhanced tissue boron uptake and delayed tumor growth in a rat subcutaneous tumor model.

Yoshida F, Yamamoto T, Nakai K, Kumada H, Shibata Y, Tsuruta W, Endo K, Tsurubuchi T, Matsumura A

University of Tsukuba, Graduate School of Comprehensive Human Sciences, Functional and Regulatory Medical Sciences, Tennodai 1-1-1, Tsukuba, Ibaraki 305-8575, Japan. yoshi234@sakura.cc.tsukuba.ac.jp

We have previously reported that buthionine sulfoximine (BSO) enhances sodium borocaptate (BSH) uptake by down regulating glutathione (GSH) synthesis in cultured cells. This study investigated the influence of BSO on tissue BSH uptake in vivo and the efficacy of BSH-BSO-mediated boron neutron capture therapy (BNCT) on tumor growth using a Fisher-344 rat subcutaneous tumor model. With BSO supplementation, boron uptake in subcutaneous tumor, blood, skin, muscle, liver, and kidney was significantly enhanced and maintained for 12h. Tumor growth was significantly delayed by using BSO. With further improvement in experimental conditions, radiation exposure time, together with radiation damage to normal tissues, could be reduced.

Published 14 April 2008 in Cancer Lett, 263(2): 253-8.
Full-text of this article is available online (may require subscription).

© 2004-2008 Radiotherapy Research Today. All Rights Reserved.